Abstract
ObjectivesPsoriasis is associated to endothelial dysfunction, which causes impaired vascular functioning. TNF-α blockers have shown the ability to improve vascular functioning in psoriasis. The nailfold vessel resistance index (NVRI) assesses microvascular functioning at nailfold. The objectives of the study are to assess the effect of the TNF-α inhibition with adalimumab on NVRI. Material and methodsQuasi-experimental study. Fifteen patients with moderate-severe psoriasis received adalimumab 40mg sc according to label information. Participants were assessed at baseline and at 12, 24 and 52 weeks after study intervention. ResultsA reduction of −0.09±0.02 (p<.01) in NVRI and a −11.2±2.41ng/ml (p<.001) in E-selectin was observed at week 52. ConclusionsAdalimumab could produce a progressive and sustained reduction of vessel resistance at nailfold and E-selectin in patients with psoriasis.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
